Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 04, 2024 01:00 ET
|
Ultimovacs ASA
Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101...
Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
March 25, 2024 02:00 ET
|
Ultimovacs ASA
Oslo, March 25, 2024, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") at 14:00 CET on April 18, 2024. The General Meeting will be held...
Ultimovacs ASA: Mandatory notification of trade by primary insider
March 22, 2024 08:27 ET
|
Ultimovacs ASA
Oslo, March 22, 2024, Board member Henrik Schüssler and primary insider in Ultimovacs ASA, has today through FireH AS bought 50,000 shares in the company at a price of NOK 6.398 per share. Following...
Ultimovacs ASA: Annual Report 2023
March 21, 2024 02:00 ET
|
Ultimovacs ASA
Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs...
Ultimovacs ASA: Mandatory notification of trades by primary insider
March 09, 2024 05:00 ET
|
Ultimovacs ASA
Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an...
Ultimovacs ASA: Mandatory notification of trades by primary insider
March 08, 2024 17:00 ET
|
Ultimovacs ASA
Oslo, 8 March 2024: CGS Holding AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of...
Ultimovacs ASA: Mandatory notification of trade by primary insiders
March 07, 2024 17:00 ET
|
Ultimovacs ASA
Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, has today sold 596,006 shares in the company at an average...
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
March 07, 2024 01:00 ET
|
Ultimovacs ASA
With the 18-month minimum follow-up of the patients in the INITIUM trial, the trial did not meet the primary endpoint of prolonging progression-free survival (PFS). Median PFS was not reached in...
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
March 02, 2024 12:41 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially...
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
February 19, 2024 01:00 ET
|
Ultimovacs ASA
The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival...